These novel time-dependent transfusion burden analyses demonstrate that momelotinib is associated with anemia-related benefits in most patients and greater transfusion burden reduction versus comparators.

Of these, 29% did not have features consistent with anti-MDA5 disease. However, when present, MDA5 disease is severe with a high mortality.

P1, N=12, Not yet recruiting, Beijing Tiantan Hospital

Upadacitinib efficacy, including very low rates of radiographic progression, was demonstrated through 104 weeks in treatment-refractory patients with active AS. Treatment was well tolerated, with no newly identified safety signals.

P4, N=100, Recruiting, Incyte Corporation | Trial completion date: Sep 2024 --> Feb 2025 | Trial primary completion date: Sep 2024 --> Feb 2025

P4, N=308, Not yet recruiting, University Hospital, Toulouse

P1, N=10, Not yet recruiting, Northwestern University

P=N/A, N=10, Not yet recruiting, Peking University Hospital of Stomatology; Peking University Hospital of Stomatology

P=N/A, N=28, Not yet recruiting, The First Affiliated Hospital, School of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University

P4, N=300, Not yet recruiting, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

P1/2, N=120, Completed, The First Affiliated Hospital of Zhejiang University School of Medicine; Hangzhou Biosun Pharmaceutical Co., LTD

P2, N=6, Terminated, Medical College of Wisconsin | Trial completion date: May 2027 --> Oct 2024 | Active, not recruiting --> Terminated; After 6 patients were enrolled, it was determined that only patients with STAT5 activation were having a biochemical response to pacritinib treatment.

P2, N=30, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting --> Active, not recruiting

P2, N=82, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025

P2, N=25, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting

P3, N=204, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Aug 2025

P2, N=40, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Trial primary completion date: Jun 2024 --> Oct 2024

P2, N=102, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Trial primary completion date: Jun 2024 --> Oct 2024

P1, N=476, Completed, Taro Pharmaceuticals USA

P1, N=10, Not yet recruiting, City of Hope Medical Center

P2, N=41, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Jan 2025 --> Dec 2026 | Trial primary completion date: Jan 2025 --> Dec 2025

In concordance with studies of background risk, AEs were more common in patients with CV risk enrichment, particularly those aged ≥ 65 years. Tofacitinib effectiveness/persistence were generally similar regardless of CV risk enrichment. These findings support individualised treatment benefit-risk assessment, including CV assessment/management, to optimise RA outcomes.

Our findings suggest that tofacitinib may reduce the risk of all-cause mortality in patients with anti-MDA5 antibody-positive DM-ILD without an increased risk of additional infections. PROSPERO: CRD42023445427; https://www.crd.york.ac.uk/prospero/.

P2, N=16, Terminated, University of California, San Francisco | Completed --> Terminated; Low accrual

P2, N=28, Recruiting, Jonathan Brammer | Trial primary completion date: Dec 2024 --> Dec 2025

P3, N=134, Not yet recruiting, McMaster University

P2, N=120, Not yet recruiting, H. Lee Moffitt Cancer Center and Research Institute

P3, N=843, Completed, Astellas Pharma Inc | Phase classification: P2b --> P3

Our results revealed the relationships among the ERα, PI3K/AKT, and MAPK signaling pathways in ER+ breast cancer cells. Understanding the interactions among ERα, PI3K-AKT-mTOR, and MAPK could lead to novel combination therapies.

Case Report: Here, we describe a case in which upadacitinib, a JAK1-selective inhibitor, was used to manage a severe RA flare-up occurring during ICI therapy with pembrolizumab, an anti-programmed cell death protein-1 antibody. We did not observe recurrence of lung cancer for more than 1 year during upadacitinib therapy. Upadacitinib could be a safe and effective option to treat severe RA flare-ups occurring during anti-PD-1 ICI therapy.

With respect to immunosuppressive treatment used to control RA, it was observed that glucocorticoids (especially high-dose usage) and Rituximab (RTX) predispose the patients to poor SARS-CoV-2 outcomes, as opposed to Baricitinib and interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) inhibitors. COVID-19 vaccination has proven effective and generally safe for RA patients in some studies, although therapies with Methotrexate (MTX), Abatacept (ABA), and RTX have been associated with impaired vaccine immune response. This systematic literature review brings updated and thorough information with respect to the immunological, clinical, and management of a complex immune-mediated inflammatory disease (IMID) like RA in the setting of COVID-19 and underlines the challenges faced by this group of patients. The lessons learned can be extended beyond the pandemic in shaping a more informed and compassionate healthcare system and offering long-term medical care for patients with RA.

Then we detected 6 repurposable drug molecules (Entrectinib, Imatinib, Ponatinib, Sorafenib, Retevmo, and Pazopanib) by molecular docking with KGs-mediated receptor proteins, ADME/T analysis, and cross-validation with the independent receptors. Therefore, these findings might be useful resources for wet lab researchers and clinicians to consider an effective treatment strategy against THCA.

P1/2, N=147, Active, not recruiting, NRG Oncology | Trial completion date: Sep 2022 --> Aug 2025

Furthermore, the elevated production of inflammatory cytokines observed in 3CK-treated hiPSC-COs was attenuated by treatment with tofacitinib. Our UC model will be an essential tool to understand its pathologic mechanisms and identify effective therapeutic approaches.

P3, N=0, Withdrawn, Vanderbilt University Medical Center | N=550 --> 0 | Not yet recruiting --> Withdrawn

Various therapies have been discovered for psoriasis, including topical treatments, phototherapy, conventional systemic agents such as methotrexate, retinoids and ciclosporine, as well as biologics...Ruxolitinib cream has been investigated in various dermatologic diseases, including atopic dermatitis, vitiligo, psoriasis, and alopecia areata. However, there is limited data on the efficacy of oral ruxolitinib in patients with psoriasis vulgaris. Here, we report a patient diagnosed with myelofibrosis coexisting with psoriasis vulgaris, successfully treated with oral ruxolitinib.

P1/2, N=54, Recruiting, Veronika Bachanova | Trial completion date: Dec 2026 --> Jul 2027 | Trial primary completion date: Sep 2024 --> Jul 2025

P1, N=15, Completed, Astellas Pharma Inc | Phase classification: P1b --> P1

P2, N=281, Completed, Astellas Pharma Inc | Phase classification: P2b --> P2

P2, N=289, Completed, Astellas Pharma Global Development, Inc. | Phase classification: P2b --> P2

P2, N=379, Completed, Astellas Pharma Inc | Phase classification: P2b --> P2

P1/2, N=55, Recruiting, Masonic Cancer Center, University of Minnesota | Trial primary completion date: Sep 2024 --> Sep 2025